Southwest Immunology, Inc. (SWI), was founded in 1984 and is located in Ennis, Texas, the official Bluebonnet capital of the state. The animal facilities for producing antibodies are located east of Ennis in the town of Bristol on a family-owned farm operating since 1869. 

        Originally, the company was set up to support research in the field of Alzheimer’s disease.  Since that time, SWI has expanded its line of products and now specializes in neuroscience antibodies for research in the field of degenerative neurological diseases, particularly Alzheimer’s, Parkinson’s and Prion diseases.

        The year 1995 was momentous for both the field of Alzheimer’s disease research and SWI when a presenilin gene was cloned for a hereditary form of Alzheimer’s disease. At that time, the company realized the potential to bring this and other exciting new antibodies to the market.  Having the expertise and available facilities, SWI began using larger animals to accommodate the expansion of its operations.  Within a matter of months following the gene’s publication, SWI was the first to commercially introduce a peptide antibody to the presenilin-1 protein.

        Since that time, SWI has been the first to market several other products, including the Parkin peptide antibody. The number of antibodies produced by SWI has increased dramatically and the company has also seen expansion into international markets.  SWI constantly monitors research in the various fields of degenerative neurological diseases for possible new antibodies.  As a result, “cutting edge” products are currently in various stages of planning.

        Research utilizing SWI antibodies has been published in a number of noted journals including NeuroReport.  Immunofluorescent pictures using one of SWI’s antibodies was featured on the front cover of the journal FEBS Letters (January 2000).    

      Working in a new direction, SWI is collaborating with researchers in developing antibodies to measure oxidative stress, which may play an early role in neuronal degeneration and may have an application in testing the efficacy of antioxidant supplements. 

        SWI’s role as a partner isn’t limited to producing antibodies, but the company works closely with its customers by answering questions and providing technical assistance.  SWI is dedicated to providing quality products and service for its customers.

[Home ] [Products] [New Products] [Protocols] [Contact Us]